Overall, we found that patients with the GSTP1 rs1695 AA genotype had a lower risk of tumor recurrence when treated with epirubicin, but not with MMC ((AG+GG)/AA: HR = 3.47, 95% CI = 1.75–6.89). This evidence concerns the gene GSTP1 and neoplasm.